← FDA DRUG APPROVALS
FDA ANDA · ANDA218069
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Sponsor: NOVAST LABS LTD
APPLICATION
ANDA218069
TYPE
ANDA
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
None (Tentative Approval)
Products
SITAGLIPTIN AND METFORMIN HYDROCHLORIDENone (Tentative Approval)
METFORMIN HYDROCHLORIDE, SITAGLIPTIN 1000MG · TABLET, EXTENDED RELEASE
SITAGLIPTIN AND METFORMIN HYDROCHLORIDENone (Tentative Approval)
METFORMIN HYDROCHLORIDE, SITAGLIPTIN 500MG · TABLET, EXTENDED RELEASE
SITAGLIPTIN AND METFORMIN HYDROCHLORIDENone (Tentative Approval)
METFORMIN HYDROCHLORIDE, SITAGLIPTIN 50MG · TABLET, EXTENDED RELEASE
SITAGLIPTIN AND METFORMIN HYDROCHLORIDENone (Tentative Approval)
METFORMIN HYDROCHLORIDE, SITAGLIPTIN EQ 100MG BASE TABLET · TABLET, EXTENDED RELEASE
Approval history
2025-05-28UNKNOWN · Original · standardTA
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.